Gossamer Bio, Inc. (GOSS)
| Market Cap | 80.74M |
| Revenue (ttm) | 48.47M |
| Net Income (ttm) | -170.37M |
| Shares Out | 234.70M |
| EPS (ttm) | -0.75 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 7,636,582 |
| Open | 0.341 |
| Previous Close | 0.349 |
| Day's Range | 0.327 - 0.346 |
| 52-Week Range | 0.320 - 3.870 |
| Beta | 2.16 |
| Analysts | Buy |
| Price Target | 4.19 (+1,118.02%) |
| Earnings Date | May 14, 2026 |
About GOSS
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup comp... [Read more]
Financial Performance
In 2025, Gossamer Bio's revenue was $48.47 million, a decrease of -57.74% compared to the previous year's $114.70 million. Losses were -$170.37 million, 201.4% more than in 2024.
Financial StatementsAnalyst Forecast
According to 8 analysts, the average rating for GOSS stock is "Buy." The 12-month stock price target is $4.19, which is an increase of 1,118.02% from the latest price.
News
GOSS Stockholders Have Rights – If You Lost Money Investing in Gossamer Bio, Inc. Contact Robbins LLP for Information About Recovering Your Losses
SAN DIEGO, April 20, 2026 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Gossamer Bio, Inc. (NASDAQ: ...
Gossamer Bio, Inc. (GOSS) Securities Fraud: Contact Berger Montague To Discuss Your Rights
Philadelphia, Pennsylvania--(Newsfile Corp. - April 20, 2026) - National plaintiffs' law firm Berger Montague PC announces a class action lawsuit against Gossamer Bio, Inc. (NASDAQ: GOSS) ("Gossamer" ...
Shareholders who lost money in Gossamer Bio, Inc (NASDAQ: GOSS) Should Contact Wolf Haldenstein Immediately
NEW YORK, April 13, 2026 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP announces that a class action lawsuit has been filed on behalf of shareholders who purchased or otherwise acquire...
Gossamer Bio Announces Fourth Quarter and Full-Year 2025 Financial Results and Provides Corporate Update
SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hyper...
Top 3 Health Care Stocks That Could Lead To Your Biggest Gains In Q1
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
GOSS Investors Have Opportunity to Join Gossamer Bio, Inc. Fraud Investigation with the Schall Law Firm
LOS ANGELES--(BUSINESS WIRE)---- $GOSS--GOSS Investors Have Opportunity to Join Gossamer Bio, Inc. Fraud Investigation with the Schall Law Firm.
BREAKING: Gossamer Bio Investors Should Contact Block & Leviton to Potentially Recover Losses After Shares Fall Over 75%
Block & Leviton is investigating Gossamer Bio, Inc. (Nasdaq: GOSS) for potential securities fraud. Investors should contact the firm to recover losses.
Gossamer Bio Shareholders Are Encouraged to Contact Johnson Fistel for More Information About Potentially Recovering Their Losses
SAN DIEGO, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Gossamer Bio, Inc. (NASDAQ: GOSS). The investigation focuses on Gossamer's...
Gossamer Bio Plans FDA Talks After Narrow Miss In Key Pivotal Study, Stock Sinks
Gossamer Bio Inc. (NASDAQ: GOSS) dropped during early trading on Monday after the company shared topline results from the Phase 3 PROSERA study evaluating seralutinib in pulmonary arterial hypertensio...
Gossamer Bio Transcript: Study result
The PROSERA phase III trial in PAH showed seralutinib improved 6MWD but narrowly missed statistical significance in the overall population due to a high placebo response, especially in Latin America. Clinically meaningful and statistically significant benefits were observed in high-risk and CTD subgroups, with a manageable safety profile.
Gossamer Bio's experimental lung condition drug fails in late-stage trial
Gossamer Bio said on Monday its experimental drug missed the main goal of a late-stage study in patients with a serious lung and heart condition.
Gossamer Bio Announces Topline Results from the Phase 3 PROSERA Study Evaluating Seralutinib in Pulmonary Arterial Hypertension
SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS) a biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypert...
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pul...
Gossamer Bio to Participate in Upcoming Investor Conferences
SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pul...
Gossamer Bio Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference
Seralutinib’s phase 3 Prosera trial is set for a key data readout in February, with a focus on sicker patients and a differentiated safety profile. Commercial launch is targeted for late Q2 2027, with expansion into PH-ILD and a strengthened pipeline through recent asset acquisition.
Gossamer Bio Announces Third Quarter 2025 Financial Results and Provides Business Update
SAN DIEGO--(BUSINESS WIRE)---- $GOSS--Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatm...
Gossamer Bio Transcript: Emerging Growth Conference
Major phase 3 data for seralutinib in PAH is expected in February, with a second phase 3 in PH-ILD planned by year-end, targeting a combined market over $20 billion. Seralutinib's strong safety and efficacy profile, plus the addition of RT234, positions the pipeline for global leadership.
Respira Therapeutics Enters into Agreement with Gossamer Bio (Gossamer) Granting Gossamer Option to Acquire Respira from Samsara BioCapital
- Transaction designed to accelerate development of RT234 (vardenafil Inhalation powder), an investigational first-in-class, as-needed (PRN) treatment for PAH and PH-ILD - PALO ALTO, Calif. , Sept. 25...
Gossamer Bio Enters into Option Agreement to Acquire Respira Therapeutics and Its Lead Candidate, RT234, an Inhaled, On‑Demand Vardenafil for Pulmonary Hypertension
SAN DIEGO--(BUSINESS WIRE)---- $GOSS--Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatm...
Gossamer Bio Announces Presentations at the European Respiratory Society (ERS) Congress 2025
SAN DIEGO--(BUSINESS WIRE)---- $GOSS--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of...
Gossamer Bio Transcript: Cantor Global Healthcare Conference 2025
Transitioning to commercialization, the company is preparing for a 2027 launch of seralutinib, with robust phase 3 trials in PAH and PH-ILD. Strong efficacy, safety, and operational synergies are expected to support market entry and expansion into new indications.
Gossamer Bio to Present at Upcoming Investor Conferences
SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pul...
Gossamer Bio Announces Second Quarter 2025 Financial Results and Provides Business Update
SAN DIEGO--(BUSINESS WIRE)---- $GOSS--Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatm...
Gossamer Bio Announces Completion of Enrollment in Registrational Phase 3 PROSERA Study for the Treatment of PAH
SAN DIEGO--(BUSINESS WIRE)---- $GOSS--Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatm...
Gossamer Bio Transcript: Emerging Growth Conference 82
Copperwood is advancing toward construction with full permits, detailed engineering, and strong community and legislative support. Environmental mitigation and metallurgical testing are underway, with project financing targeted for early 2026 and new federal funding opportunities expected.